Treatment of systolic hypertension: Spotlight on recent studies with angiotensin II antagonists

Journal of Human Hypertension

Volumn 19, Issue 2, 2005, Pages 93-102

  Volpe, M ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Angiotensin II antagonists; Beta blockers; Cardiovascular disease; Diuretics; Isolated systolic hypertension; Losartan; Systolic hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CHLORTALIDONE; COLLAGEN; DIURETIC AGENT; ELASTIN; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTERY COMPLIANCE; ARTERY INTIMA PROLIFERATION; ARTERY WALL; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOKALEMIA; IMPOTENCE; INTIMA; ISCHEMIC HEART DISEASE; LETHARGY; LIFE EXPECTANCY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; MUSCLE WEAKNESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT PLANNING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYPERTENSION; LOSARTAN; PATIENT COMPLIANCE; PRACTICE GUIDELINES; SYSTOLE;

EID: 13544257457     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001781     Document Type: Review

References (90)

1. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
2. McInnes GT. Systolic hypertension as a cardiovascular risk factor. Blood Press 2002; 11: 134-143.
3. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999; 34: 386-387.
4. Deedwania PC. The changing face of hypertension: is systolic blood pressure the final answer? Arch Intern Med 2002; 162: 506-508.
5. Izzo Jr JL, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35: 1021-1024.
6. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138: 211-219.
7. Klag MJ et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
8. Klahr S et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884.
9. Chobanian AV et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
10. Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
11. European Society of Hypertension - European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
12. McInnes GT. Angiotensin II antagonists in systolic blood pressure control. Hosp Med 2001; 62: 773-777.
13. Tonkin A, Wing L. Management of isolated systolic hypertension. Drugs 1996; 51: 738-749.
14. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994; 23: 275-285.
15. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). (SHEP Cooperative Research Group). JAMA 1991; 265: 3255-3264.
16. Staessen JA et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
17. Liu L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-1829.
18. Mancia G, Seravalle G, Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20 Suppl 5): S21-S27.
19. Izzo Jr JL. Systolic hypertension, arterial stiffness, and vascular damage: role of the renin-angiotensin system. Blood Press Monit 2000; 5(Suppl 2): S7-S11.
20. Franklin SS et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
21. Franklin SS et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37: 869-874.
22. Swales JD. Current status of hypertensive disease treatment: results from the evaluation and interventions for systolic blood pressure elevation: regional and global (EISBERG) project. J Hypertens Suppl 1999; 17: S15-S19.
23. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 1990; 15: 339-347.
24. Izzo Jr JL, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2001; 2: 29-40.
25. Nawrot T, Den Hond E, Thijs L, Staessen JA. Isolated systolic hypertension and the risk of vascular disease. Curr Hypertens Rep 2003; 5: 372-379.
26. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-255.
27. Gubner RS. Major new developments affecting treatment and prognosis in hypertension. Trans Assoc Life Insur Med Dir Am 1990; 73: 97-114.
28. Gubner RS. Systolic hypertension: a pathogenetic entity. Significance and therapeutic considerations. Am J Cardiol 1962; 9: 773-776.
29. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56: 43-52.
30. Kannel WB et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981; 245: 1225-1229.
31. Miall WE. Systolic or diastolic hypertension - which matters most? Clin Exp Hypertens A 1982; 4: 1121-1131.
32. Incidence and prediction of coronary heart disease in two Italian rural population samples followed-up for 20 years. Acta Cardiol 1982; 37: 129-145.
33. Yano K, McGee D, Reed DM. The impact of elevated blood pressure upon 10-year mortality among Japanese men in Hawaii: the Honolulu Heart Program. J Chronic Dis 1983; 36: 569-579.
34. Lichtenstein MJ, Shipley MJ, Rose G. Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study. Br Med J (Clin Res Ed) 1985; 291: 243-245.
35. Rosenman RH, Sholtz RI, Brand RJ. A study of comparative blood pressure measures in predicting risk of coronary heart disease. Circulation 1976; 54: 51-58.
36. Tverdal A. Systolic and diastolic blood pressures as predictors of coronary heart disease in middle aged Norwegian men. Br Med J (Clin Res Ed) 1987; 294: 671-673.
37. Prognostic factors in the treatment of mild hypertension. The Management Committee of the Australian National Blood Pressure Study. Circulation 1984; 69: 668-676.
38. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242: 2562-2571.
39. Amery A et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 2: 589-592.
40. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291: 97-104.
41. Pastor-Barriuso R et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139: 731-739.
42. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598-615.
43. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
44. Williams B et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-640.
45. Whitworth JA, WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
46. Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999; 138: 231-237.
47. Mancia G et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002; 162: 582-586.
48. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 1461-1464.
49. Neaton JD et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
50. Cushman WC, Brady WE, Gazdick LP, Zeldin RK. The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens (Greenwich) 2002; 4: 101-107.
51. Farsang C et al. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000; 18: 795-801.
52. Volpe M et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25: 1469-1489.
53. Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl 1999; 17 S21-S25.
54. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8: 114-121.
55. Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001; 10: 223-229.
56. Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged>or=65 years with systolic hypertension. Clin Ther 2000; 22 961-969.
57. Malacco E et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther 2003; 25: 2765-2780.
58. Wing LM, Arnolda LF, Upton J, Molloy D. Candesartan and hydrochlorothiazide in isolated systolic hypertension. Blood Press 2003; 12: 246-254.
59. Neutel JM et al. The effects of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial. J Clin Hypertens (Greenwich) 2000; 2: 181-186.
60. Weir MR et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001; 14: 567-572.
61. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56 1039-1044.
62. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529.
63. Manolis AJ et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hypertens 2004; 22: 1033-1037.
64. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999-1028.
65. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged> or =65 years with mild to moderate hypertension. Clin Ther 2000; 22: 1213-1224.
66. Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003; 37: 99-105.
67. Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 2003; 25: 1041-1055.
68. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-432.
69. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-1353.
70. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
71. Douglas JG et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525-541.
72. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000; 54: 48-54.
73. Lacourciere Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003; 16: 1036-1042.
74. Conlin PR et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
75. Dahlof B et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705-713.
76. Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-1498.
77. Alderman M, Aiyer KJV. Uric acid - role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369-379.
78. Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 995-1003.
79. Schupp M et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
80. Julius S et al. VALUE trial: long-term blood pressure trends in 13 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-548.
81. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004, 1-10.
82. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003; 21(Suppl 6): S37-S46.
83. Nelson EC, Stason WB, Neutra RR, Solomon HS. Identification of the noncompliant hypertensive patient. Prev Med 1980; 9: 504-517.
84. Croog SH et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
85. Okereke CE, Messerli FH. Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. Am J Geriatr Cardiol 2001; 10: 42-49.
86. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
87. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32 1060-1066.
88. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
89. Oparil S et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18: 608-625.
90. Weir MR et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411-428.